TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03822013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat
Description: Treatment with Zavesca regimen based on body surface area as follows: SQRT \[Height (cm) × Weight (kg)\] / 3600 \<1.25 : 200mg TDS 0.88- 1.25: 200mg BID 0.73- 0.88: 100 mg TDS 0.47- 0.73: 100 mg BID \<0.47: 100 mg Daily
Study: NCT03133195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide 20 μg subcutaneous once daily for 12 weeks (Patient self administration at home by pen injector)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous once daily for 12 weeks. (Patient self administration at home by pen injector)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium supplement
Description: 1000 mg/day of elemental calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: 1000 mg/day of elemental calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: 20,000 IU/week of vitamin D2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 20,000 IU/week of vitamin D2
Study: NCT06636474

Intervention type: OTHER
Group type: OTHER
Intervention: patients with mental disorders
Description: administration of standardized questionnaires and scales, upon entering the research, then annually, and finally upon leaving the research
Study: NCT02292433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 low dose
Description: tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
Study: NCT03508934

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GTS (Continuous Glucose Monitoring)
Description: Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: POC (Point of Care)
Description: Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: POC (Point of Care)
Description: Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.
Study: NCT02292433

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, breakfast plus lunch, 7 days
Study: NCT04304326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistence Exercise
Description: Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises was 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistence Exercise
Description: Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises was 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension.
Study: NCT01316133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral
Study: NCT03293940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: The cryoablation procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle(s) in place, the study doctor(s) will freeze the nerve over 5 minutes. A 3 minutes thaw will follow, then a second 5 minutes freeze and a final 3minute thaw. This portion of the procedure can last from 25 to 45 minutes. Once the nerve has been properly treated, the cryoablation needle(s) will be withdrawn.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Peripheral Nerve Block (tPNB) Injection
Description: During the nerve block procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area and anesthetic will be injected into the targeted area.~The tPNB injection consists of 4 cc of 0.25% Bupivicaine and 1 cc of 6mg/ml betamethasone.
Study: NCT00352729

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACell dressing
Description: dressing
Study: NCT03296995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring system
Description: Flash glucose monitoring systems in critically ill patients may improve glycemic control and reduce glucose variability.
Study: NCT03497923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: After reversal the obention of a TOF ratio of 0.9 is avaited. 10 minutes later patients will receive a perfusion of magnesium 60 mg kg-1 over 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: After reversal the obention of a TOF ratio of 0.9 is avaited. 10 minutes later patients will receive a perfusion of magnesium 60 mg kg-1 over 5 minutes.
Study: NCT01169571

Intervention type: DRUG
Intervention: Dexmedetomidine

Intervention type: DRUG
Intervention: Dexmedetomidine

Intervention type: DRUG
Intervention: Dexmedetomidine
Study: NCT00524693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 4mg sachets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo granules
Study: NCT02420938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab
Description: 8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
Study: NCT04453306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: topiramate 25mg is coated in tablets in an independent laboratory
Study: NCT02951325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant RT
Description: Radiation therapy:~All patients will be offered conformal technique with IMRT +/- image guidance. The adjuvant RT will start within 8 weeks from the date of surgery if chemotherapy not planned or 4 weeks from the date of last adjuvant chemo cycle.~Dose:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) for the nodal PTV. For R1 and/or R2 resection increased to 54-56 Gy in 28 fractions based on the constraints achieved during planning.~Patient assessments:~Clinical:~* Toxicity:~  1. Weekly RT with toxicity scoring.~ 2. RTOG toxicity criteria at baseline, 6-8 weeks post RT and f/b 3 monthly x 2 years and 6 monthly x 5 years.~ 3. QOL will be assessed at baseline f/b 3-6 monthly.~* Disease evaluation:~  i. first f/u all patients will be at 6-8 week to assess toxicity. ii. Clinical evaluation of the disease will be done at each f/u visit. iii. CT scan (abdomen and pelvis) 6 monthly from visit 2 onwards up to 2 years f/b 12 monthly or as clinically indicated.
Study: NCT03772080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early counseling of prematurity in high-risk pregnancies.
Description: Standardized information regarding prematurity, including associated complications and ways to decrease chances of preterm birth using web-based educational platform.
Study: NCT04453306

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: innocuous substance is coated in tablets in an independent laboratory
Study: NCT01519713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide diphtheria toxoid conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide diphtheria toxoid conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide diphtheria toxoid conjugate
Description: 0.5 mL, Intramuscular
Study: NCT03453606

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home respiratory rehabilitation
Description: Home care is individual (often with the spouse or the carer), during 1h30, one visit per week for 8 weeks, after completion of the educational diagnosis, under direct supervision of a member of the team, with continued physical activities in autonomy the others days of the week, according to a personalized action plan. No visit is scheduled in the pulmonologist, the general practitioner or in the rehabilitation center. The team includes pulmonologist, nurses, dietician, socio-medical beautician and a administrative assistant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Center respiratory rehabilitation
Description: In an outpatient setting, the course is performed in groups of 6 to 8 patients, during sessions from 3 to 7 am, under the direction of health professionals, 3 to 5 times a week, for 4 to 6 weeks, for a total of 20 to 24 sessions. Internally, patients come to complete hospitalization for 4 weeks. This duration can be modulated according to the evolution of the patients.~Supervision is carried out by the entire team including pulmonologists, nurses, physiotherapists, psychologists, activity professors adapted physicists, dietician
Study: NCT03124641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated perfusion (HOPE)
Description: HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cold storage (CCS)
Description: Conventional static cold storage (CCS) on temperature 4-6 °C from organ procurement
Study: NCT02712385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 'The Healthy Brain Rehabilitation Manual'
Description: The Healthy Brain Rehabilitation Manual is a home-based rehabilitation manual developed for the post-TIA and minor stroke population caused by ischaemic events. The manual addresses all the secondary prevention factors required post-ischaemic TIA/minor stroke, e.g. smoking cessation, physical activity promotion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 'The Healthy Brain Rehabilitation Manual'
Description: The Healthy Brain Rehabilitation Manual is a home-based rehabilitation manual developed for the post-TIA and minor stroke population caused by ischaemic events. The manual addresses all the secondary prevention factors required post-ischaemic TIA/minor stroke, e.g. smoking cessation, physical activity promotion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 'The Healthy Brain Rehabilitation Manual'
Description: The Healthy Brain Rehabilitation Manual is a home-based rehabilitation manual developed for the post-TIA and minor stroke population caused by ischaemic events. The manual addresses all the secondary prevention factors required post-ischaemic TIA/minor stroke, e.g. smoking cessation, physical activity promotion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer
Description: Pedometer used to measure step counts as an objective measurement of level of physical activity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer
Description: Pedometer used to measure step counts as an objective measurement of level of physical activity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care provided by healthcare system for patients who suffer a TIA or minor stroke will be recorded and form 'active comparator' control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care provided by healthcare system for patients who suffer a TIA or minor stroke will be recorded and form 'active comparator' control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care provided by healthcare system for patients who suffer a TIA or minor stroke will be recorded and form 'active comparator' control.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone follow-up
Description: Telephone follow-up by either a General Practitioner (GP) or Stroke nurse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone follow-up
Description: Telephone follow-up by either a General Practitioner (GP) or Stroke nurse.
Study: NCT01201954

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Description: oral sucrose solution, 24%, 0,5 ml/kg, 2 minutes before start the suctioning sterile water, 0,5 ml/kg, 2 minutes before start the suctioning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sucrose
Description: oral sucrose solution, 24%, 0,5 ml/kg, 2 minutes before start the suctioning sterile water, 0,5 ml/kg, 2 minutes before start the suctioning
Study: NCT01423565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (Medtronic, Activa PC)
Description: Following subthalamic nucleus deep brain stimulation patients will be randomized to receive either constant current or constant voltage stimulation and subsequently crossed over to receive the other type of stimulation
Study: NCT00597207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoPulse
Description: Mechanical device that provides chest compression

Intervention type: OTHER
Group type: OTHER
Intervention: Manual
Description: Manual chest compression
Study: NCT04323007

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nephrotic patients
Description: Laboratory measures will include Blood sugar Urine analysis with 24hrs protein in urine Complete blood count Liver function tests Kidney functions test Plasma lipid levels Thyroid functions test Abdominal ultrasound Antithyrperoxidase Renal biopsy
Study: NCT02058433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dosage of paclitaxel
Description: Based on pharmacokinetics. Observe the toxicity in an individual patient after a fixed Paclitaxel dose depending on BSA and then the dosage of Paclitaxel is adjusted depending on pharmacokinetics follow up to avoid excess toxicity in subsequent cycles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dosage of paclitaxel
Description: Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
Study: NCT01265888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM
Study: NCT00764998

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluviral

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fluviral
Study: NCT01562574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
Study: NCT02722746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.
Study: NCT01829412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DW-MRI
Description: MRI imaging with diffusion weighted sequences of the whole body
Study: NCT03786913

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative muscle ultrasound measurements
Description: Quantitative ultrasound measurements will be performed to biceps, forearm flexors, quadriceps and tibialis anterior according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.
Study: NCT04158375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Participants will complete 2 progressing to 4 sets of 8 to 12 repetitions per exercise, with 1 minute rest between sets. Participants will warmup for 5 minutes on a treadmill, cycle ergometer or elliptical at \~50% VO2 peak then begin resistance training. Resistance will be performed 4 days per week with lower body exercise on Monday and Thursday, and upper body on Tuesday and Friday. Wednesdays are a rest day. Participants will begin at 2 sets per exercise on weeks 1 and 2, then 3 sets for week 3, and 4 sets for weeks 4 to 12.
Study: NCT03571295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: King Vision aBlade
Description: endotracheal intubation performed with King Vision aBlade

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: direct laryngoscopy
Description: endotracheal intubation performed with direct laryngoscopy
Study: NCT02043782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test
Description: Newly developed 1-piece convex ostomy product

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test
Description: Newly developed 1-piece convex ostomy product

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test
Description: Newly developed 1-piece convex ostomy product

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Own product
Description: The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Own product
Description: The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Own product
Description: The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Competitor soft convex
Description: A commercially available soft convex product

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Competitor soft convex
Description: A commercially available soft convex product

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Competitor soft convex
Description: A commercially available soft convex product
Study: NCT05326152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine immunotherapy of common warts (GeneVac-B 10 ml vial, Serum Institute of India Ltd., Pune, India)
Description: Randomized placebo-controlled comparative effectiveness clinical trial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine immunotherapy of common warts (GeneVac-B 10 ml vial, Serum Institute of India Ltd., Pune, India)
Description: Randomized placebo-controlled comparative effectiveness clinical trial

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intralesional saline
Description: Intralesional saline
Study: NCT03381066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib, pemetrexed,cisplatin
Description: * Intercalation phase (Duration: 3weeks x 4 cycles = 12 weeks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Gefitinib 250mg D5-18, every 3week~* Maintenance phase (Duration: 1 year) Gefitinib 250mg D1-2
Study: NCT02127801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1908-1909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT03381066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine, cisplatin
Description: Duration: 3wks x 4 cycles = 12 weeks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3week